All News
After failing a JAK inhibitor, can you still hit a JAK-pot?
Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis.
Read Article
ACR21 Best Abstracts - Day 2
The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).
Read Article
Watch: Lupus Updates: Dr. Michelle Petri
Dr. Michelle Petri offers perspective and insight into lupus related data presented Saturday at the #ACR21 annual meeting.
https://t.co/L7T2mNJVH0 https://t.co/MCQ7nJjCIY
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR21 #Abstr1100 Pulmonary Hypertension is a rare complication of AOSD. What can we learn from case-series of N=13🧐 💠All were female 💠Severe at diagnosis: mean PAP 41mmHg; 85% had NYHA III&IV 💠38.5% mortality rate So, plz be aware of PAH @RheumNow https://t.co/gmXF3AzH2n https://t.co/s5CXrHYUor
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Atypical patterns of HCQ retinopathy:
- outside the central macula
- missed by standard central macula screening
- 41x more likely in Asians!
Lesson: screening with extramacular SD-OCT for Asian HCQ pts is so, so important. 41x over.
@MGHrheumatology #ACR21 ABST0989 @RheumNow https://t.co/0w7ALHJDSW
David Liew drdavidliew ( View Tweet)
#ACR21 #Abstr1083 Do pts with Autoinflammatory disease flare differently during #COVID19? Survey of N=647 (mostly CAPS):
💠56% No change
💠Of pts who flared, 50% had low/absent fever
💠7% had COVID; mostly mild
Shielding could influence results @RheumNow https://t.co/g7VazLfiT9 https://t.co/lzaSoMEzyR
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR21 #Abstr1011 Can we differentiate NEMO-deleted exon 5 autoinflammatory syndrome (NEMO-NDAS) vs CANDLE? Bioinformatics to mask the IKBKG pseudogene is promising and identified IL-6, 8,18, IFN-I and TNF-induced cell death as future targets @RheumNow https://t.co/tR2PNymMVn https://t.co/yCKHQx6R3E
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Daniela Ospina Cardona presenting at the Down and Dirty 30 on VEXAS. Marked differences in mortality depending on exact mutation. Looking forward to hearing more about this at Plenary session III today #ACR21 @RheumNow https://t.co/R3gXpxOfSk
Richard Conway RichardPAConway ( View Tweet)
Baricitinib for *relapsing* GCA (Th1+Th17)
w abbreviated steroid wean (15-22w)
Despite being tougher to treat:
100% off steroids at 24w
93% off steroids at 52w
no ischemic Sx
promising as another GCA Rx option!
(post-cessation 4pts flared)
@MayoClinic #ACR21 ABST1396 @RheumNow https://t.co/dqFnHQYogk
David Liew drdavidliew ( View Tweet)
It is #ACR21, but it is also #COP26Glasgow 🌎! What can we do for climate as physicians? "Our job is to make changes" Strong message for #ClimateAction from Dr Paul Dellaripa during his talk at the climate, pollution and IRMDs study group session @RheumNow https://t.co/GWxpzYD3lg
Aurelie Najm AurelieRheumo ( View Tweet)
"GCA is not a single, monolithic disease"
- Christian Dejaco, rightfully asking why we don't stratify treatment/trials in GCA
#ACR21 PMR/GCA Study Group @RheumNow @Sarah_L_Mackie @profbdasgupta @EBRheum @RichardPAConway @SattuiSEMD @drceowen
David Liew drdavidliew ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow and its Faculty.
Dr. John Cush RheumNow ( View Tweet)
#ACR21 Abs#0819. RheumTAP real-world cohort of pts tapering Rx in remission on RA
▶️ Pts tapering 7.6x ⬆️ likely to flare in f/u
Great convo soon on @Rheumnow re: tapering studies. @davidliew asks how many more times do we need to see drug w/d fail?
https://t.co/BiZSM7yp7o https://t.co/iDXGVpFZzB
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Rheum Pearls and Secrets
Not all (or most) ulcers is Behcet's! Here's a great approach to use in clinic. Jason Kolfenbach: "Sometimes, taking off the mask is worth it"
@Rheumnow https://t.co/OEBgf1eFhd
Eric Dein ericdeinmd ( View Tweet)
#ACR21. Powerful patient perspective by Amy Barron, RN and rheumatic patient
⭐️"I found hope advocating for arthritis" and found meaning in advocacy.
▶️ Consider talking to your patients about getting involved in ACR Advocacy to give purpose & community.
@ACRheumDC @CreakyJoints https://t.co/2mJRaShZQQ
Eric Dein ericdeinmd ( View Tweet)
Females axSpA pts presented w/ higher disease burden (fatigue/tiredness, & spinal pain at night.) Female axSpA pts achieved sign/symptom improvement with IXE later than male axSpA pts. Abs 0934 #ACR21 #RheumNow@RheumNow https://t.co/EGXnfeF6KQ https://t.co/TDF5zxtca7
Dr. Rachel Tate uptoTate ( View Tweet)
Oral Calcitonin not recommended for OA - studies did not show efficacy
Strontium Ranelate study below was considered a positive study in KOA with efficacy but had Cardiovascular toxicity - now off the market. https://t.co/gcYH9xoxeo
Bella Mehta bella_mehta ( View Tweet)
Wnt signaling - Lorecivivint is now in phase 3 https://t.co/JSk2nPBTrI
Bella Mehta bella_mehta ( View Tweet)
Abst 0789
Baker & colleagues examined adipokine levels in association with disease activity in RA patients
- Patients with high levels of adipokines less likely to achieve low disease activity & remission
- These patients more likely to escalate to b/tsDMARDs
#ACR21 @RheumNow https://t.co/1xlO4W9q9v
Akhil Sood MD AkhilSoodMD ( View Tweet)
Another exciting day at #ACR21 and covering for @RheumNow
Also presented my poster (Abstr 0587) DMARD Use in Medicare Patients with #RheumatoidArthritis and Risk of Long-Term Opioid Use
- DMARD users showed lower odds of long term opioid use compared to non-DMARD users https://t.co/2XZgYY8ORg
Akhil Sood MD AkhilSoodMD ( View Tweet)